Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

Articles and Videos

Loading...
March 9, 2022
Ophthalmology Times: Blog: Cannabinol, a rare cannabinoid, shows unique therapeutic potential in glaucoma
Excerpt from Ophthalmology Times blog. A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some...
Read More
February 22, 2022
Ophthalmology Advisor: Cannabinoids May Promote Neuroprotection, Normalize Intraocular Pressure
Excerpt from Ophthalmology Advisor. Using in vitro and in vivo models of glaucoma, cannabinoids (CBs) demonstrated neuroprotection, stopped changes in extracellular matrix (ECM), and normalized intraocular pressure (IOP) levels...
Read More
February 3, 2022
Cannabinoids See Explosive Growth Opportunity | The Dales Report
BayMedica's VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry. In...
Source: The Dales Report
Read More
January 25, 2022
InMed at Edison Open House Global Healthcare Conference 2022
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped...
Read More
January 7, 2022
InMed Pharmaceuticals (NASDAQ: INM) “Addressing The Increasing Demand For Rare Cannabinoids”
InMed's CEO, Eric A. Adams, and BayMedica's SVP and GM, Shane Johnson, and VP of Commercial Operations, Chris Meiering, join Tribe Public's Webinar "Addressing the...
Source: Tribe Public
Read More
January 6, 2022
Lytham Partners Winter Conference 2021 – InMed Talks About Addressing the Demand for Rare Cannabinoids
Lytham Partners' Robert Blum speaks with InMed Pharmaceuticals CEO, Eric A. Adams, and BayMedica's VP Commercial Operations, Chris Meiering. In this video, Eric and Chris...
Source: Lytham Partners
Read More
« Previous 1 2 3 4 … 14 Next »

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent